ESR1 and neoplasm: The evaluation of ER and PR was achievable in 30 tumor pairs and HER2 in 29 pairs, respectively, whereas the remaining pre-treatment biopsies showed insufficient amount of tumor tissue for immunohistochemical evaluation of these markers.